I'm LongbridgeAI, I can summarize articles.Mentari Therapeutics (MTRI.US) fell nearly 19% during regular trading to $13.03.
The company completed a 1-for-10 reverse stock split on Nov. 4, 2026, reducing outstanding shares to approximately 549,374 from about 5.49 million, and changed its name from InMed Pharmaceuticals to Mentari Therapeutics.
The company outlined development plans for its migraine drug pipeline. It intends to file a regulatory application for candidate MT-002 in the first quarter of 2027 and expects to release Phase 1 clinical data by year-end.
Based on public media reports. AI-generated; not investment advice.
